A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

Start Date01 Jun 2026

Sponsor / Collaborator

AIM ImmunoTech, Inc.

[+1]

NCT04093323

/ TerminatedPhase 2IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

Start Date13 Nov 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT05756166

/ TerminatedPhase 1/2IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

Start Date16 Feb 2024

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Rintatolimod

100 Translational Medicine associated with Rintatolimod

100 Patents (Medical) associated with Rintatolimod

Literatures (Medical) associated with Rintatolimod

01 Sep 2025·Journal for ImmunoTherapy of Cancer

Synergy between TLR3-ligand and IFN-α in the transient sensitization of “Cold” tumors to PD-1 blockade and the induction of systemic immunity

Article

Author: Wang, Jianmin ; Cortes-Gomez, Eduardo ; Obermajer, Natasa ; Kalinski, Pawel ; Kokolus, Kathleen M ; Connors, Eoghan L ; Huck, Connor J ; Basse, Per H

Background:

Programmed cell death protein-1 (PD-1)-blocking immune checkpoint inhibitors (ICIs) are effective against highly immunogenic “hot” tumors containing high numbers of cytotoxic T-lymphocytes (CTLs), but not against poorly immunogenic “cold” tumors. We previously reported that the combination of TLR3 agonist rintatolimod with interferon (IFN)-α selectively induces CTL-attracting chemokines (CXCL9, CXCL10, CCL5) in the tumor microenvironment (TME), but not healthy tissues, raising the possibility of their systemic application to promote local CTL attraction to TME.

Methods:

We used mouse colorectal cancer (CRC) cells implanted in syngeneic mice to test the effects of chemokine modulatory regimen (CKM) in combination with PD-1 blockade applied at different schedules. Tumor-bearing mice were treated and monitored for survival. In addition, we evaluated the reliance of CKM+αPD-1 treatment on various immune cell subsets. Finally, we observed treatment-induced changes in immune markers within TME.

Results:

Here, we report that both local or systemic application of CKM, a combination of rintatolimod and IFN-α, but not each of them individually, induces intratumoral CTL attractants and sensitizes PD-1-resistant MC38 and CT26 tumors to PD-1 blockade. The CKM/αPD-1 combination promotes intratumoral influx of BATF3-positive cDC1s and CTLs, inhibits tumor growth and prolongs survival, inducing cures in 20–100% of animals, depending on the tumor model and stage, and the route of delivery (local or systemic). CKM/αPD-1-treated mice develop local and systemic tumor-specific CTL responses and resistance to tumor re-challenge. The effectiveness of CKM requires its application at the time of or directly before PD-1 blockade and is strongly reduced by even a 24-hour delay in αPD-1 administration. CKM-driven intratumoral CTL accumulation and antitumor effects require host’s BATF3+cDC1s, CD8+T-lymphocytes, and CXCR3 and CCR5 (receptors for CXCL9/CXCL10 and CCL5).

Conclusions:

The ability of systemic CKM to eliminate the PD-1-resistance of cold tumors indicates that intratumoral CTL accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of ICI. These data suggest a broad therapeutic potential of TME-reprogramming strategies.

01 Nov 2024·Journal for ImmunoTherapy of Cancer

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer

Article

Author: O’Connor, Tracey ; Attwood, Kristopher ; Wang, Jianming ; Roudko, Vladimir ; Slomba, Ronald T ; Levine, Ellis G ; Gnjatic, Sacha ; Ioannou, Giorgio ; Cortes Gomez, Eduardo ; De Souza, Igor ; Kalathil, Suresh ; Cappuccino, Helen ; Fitzpatrick, Victoria ; Kumar, Prasanna ; Miller, Janine ; Janes, Cayla ; Ozbey, Sinem ; Takabe, Kazuaki ; Kalinski, Pawel ; Kokolus, Kathleen M ; Edge, Stephen ; Gandhi, Shipra ; Opyrchal, Mateusz ; Young, Jessica

Background:

Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30–40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.

Methods:

Phase I study NCT04081389 evaluated nine patients with early-stage TNBC who received 3 weeks of paclitaxel with CKM (dose-escalation of IFN-α2b), followed by 9 weeks of paclitaxel alone, dose-dense doxorubicin and cyclophosphamide, and surgery. Primary and secondary endpoints were safety and clinical efficacy, respectively.

Results:

The combination treatment was well-tolerated with no dose-limiting toxicities or irAEs. 5/9 patients achieved pCR and one patient had microinvasive disease (ypTmic). We observed elevated IFN signature and uniform decreases in CTL numbers (average 8.3-fold) in the blood of all treated patients. This was accompanied by reciprocal uniform increases in CD8β (overall 5.9-fold), CD8α/FoxP3 (2.11-fold), and CCL5 (4.73-fold) transcripts in TME, particularly pronounced in patients with pCR. Multiplex immunohistochemistry revealed selectively increased numbers of CTL (but not regulatory T cells) in both the epithelial and stromal tumor compartments and early decreases in the numbers of αSMA+ vascular/stromal cells in the tumors of all pCR patients.

Conclusions:

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

15 Aug 2024·Clinical cancer research : an official journal of the American Association for Cancer Research

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Article

Author: van Eijck, Casper H.J. ; van Eijck, Casper W.F. ; Mustafa, Dana A.M. ; Aerts, Joachim G.J.V. ; Kucukcelebi, Songul ; Willemsen, Marcella ; Fellah, Amine ; Vadgama, Disha ; Haddaoui, Hassana el

Abstract:

Purpose::

Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.

Experimental Design::

Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.

Results::

Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.

Conclusions::

This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

158

News (Medical) associated with Rintatolimod

28 Sep 2025

·www.globenewswire.com

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, with oncology as the fastest-growing therapeutic area Sept. 25, 2025 -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has issued a patent covering the Company’s proprietary use of Ampligen® (Rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. “We remain committed to strengthening our global intellectual property protection for Ampligen as we continue to advance its clinical development. This Japan patent – which does not expire until December 20, 2039 – further strengthens our intellectual property portfolio in one of the world’s largest oncology markets and enhances exclusivity around combination therapies that address high-need cancer indications. Importantly, this patent further reinforces our ability to advance our clinical pipeline, secure strategic collaborations, and capture value in the growing global immuno-oncology sector. The scope of this patent enhances the value for any future strategic oncology transactions,” AIM ImmunoTech CEO Thomas K. Equels stated. The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad, encompassing multiple cancer types, including pancreatic cancer, skin cancer, colorectal cancer, ovarian cancer, melanoma, breast cancer/triple negative breast cancer, head and neck tumors, bladder cancer, renal cell carcinoma, and lung cancer. The claims also capture specific dosing regimens, administration routes, and synergistic therapeutic effects observed when Ampligen is combined with checkpoint inhibitors. AIM also holds a U.S. patent (expires August 9, 2039) for methods involving use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab). The combination of these compounds is designed to work synergistically to enhance the effectiveness of the treatment. AIM believes this novel approach could revolutionize the treatment landscape for cancers that have historically been challenging to treat, such as pancreatic cancer and advanced recurrent ovarian cancer. In fact, in collaboration with AstraZeneca, Ampligen is in a Phase 2 clinical trial combined with AstraZeneca’s durvalumab (an anti-PD-L1) for the treatment of metastatic pancreatic cancer. AIM recently released a DURIPANC Mid-Year Interim Clinical Progress Update showing promising signs of superior Progression-Free Survival and Overall Survival, as well as no significant toxicity. Similarly, a Phase 2 study in collaboration with Merck Sharp & Dohme LLC in advanced recurrent ovarian cancer combing Ampligen with Keytruda has been completed and we expect the final data report within the next two months. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. The content above comes from the network. if any infringement, please contact us to modify.

Immunotherapy

24 Sep 2025

·www.globenewswire.com

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

Sept. 22, 2025 -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published a new peer-reviewed article providing evidence of a positive combination effect of AIM’s drug Ampligen and interferon-alpha on tumor growth and subsequent subject survival. The paper concluded that the ability of systemic chemokine modulation to eliminate the PD-1-resistance of cold tumors indicates that intratumoral cytotoxic t-lymphocyte accumulation, rather than tumor immunogenicity, is the key factor limiting the therapeutic effectiveness of immune checkpoint inhibitors. These data suggest a broad therapeutic potential of tumor microenvironment reprogramming strategies. The article, titled "Synergy between TLR3-ligand and IFN-α in the transient sensitization of ‘Cold’ tumors to PD-1 blockade and the induction of systemic immunity," was published in JITC on September 18. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. The content above comes from the network. if any infringement, please contact us to modify.

Immunotherapy

04 Sep 2025

·www.globenewswire.com

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland. AIM CEO Thomas K. Equels provided an overview of data from AIM’s pancreatic cancer Early Access Program and the latest advancements in the Phase 2 DURIPANC pancreatic cancer clinical trial currently underway at Erasmus University Medical Center in the Netherlands. The slides accompanying the presentation are now available on the Company’s website. “Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need. In particular, the Progression-Free Survival and Overall Survival – which are the gold standards for drug approval – seen in the clinical data demonstrated to date underscore our strong belief in the potential,” AIM ImmunoTech CEO Thomas K. Equels stated. “I am pleased to be a part of this gathering of global regulatory leaders, world-renowned oncologists and biopharma industry to share this important progress with Ampligen and highlight its potential in late-stage pancreatic cancer. We look forward to advancing its development and remain committed to bringing it to patients in desperate need and without real hope.” AIM’s drug Ampligen is currently being tested in an ongoing Phase 2 DURIPANC clinical study evaluating the combination therapy of Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor durvalumab in the treatment of late-stage metastatic pancreatic cancer patients (See: ClinicalTrials.gov NCT05927142). Ampligen has patent protection for such a combination therapy in the United States through 2039, and US and EU orphan drug designations that will grant market protections for an approved drug. For more information on Ampligen and to stay up to date with the latest advancements, please visit the Company’s website, aimimmuno.com. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5084607c-f35a-48da-8b06-10fa35de54ff Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

Phase 2Orphan DrugImmunotherapy

100 Deals associated with Rintatolimod

External Link

KEGG	Wiki	ATC	Drug Bank
D09661	Rintatolimod	L03A	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Fatigue Syndrome, Chronic	Argentina	AIM ImmunoTech, Inc.	01 Jan 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Pancreatic Adenocarcinoma	Phase 2	United States	AIM ImmunoTech, Inc.	01 Jun 2026
Metastatic Pancreatic Cancer	Phase 2	Netherlands	AIM ImmunoTech, Inc.	09 Jan 2024
Metastatic Pancreatic Cancer	Phase 2	Netherlands	AstraZeneca PLC	09 Jan 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Netherlands	AIM ImmunoTech, Inc.	09 Jan 2024
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2	Netherlands	AstraZeneca PLC	09 Jan 2024
Post Acute COVID 19 Syndrome	Phase 2	United States	AIM ImmunoTech, Inc.	30 Jun 2023
Colorectal Cancer	Phase 2	-	AIM ImmunoTech, Inc.	11 Apr 2022
acute leukemia	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020
Chronic Lymphocytic Leukemia	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020
COVID-19	Phase 2	United States	Roswell Park Comprehensive Cancer Center	17 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05927142 (DURIPANC, GlobeNewswire) Manual	Phase 2	Metastatic Pancreatic Cancer	14	rintatolimod + durvalumab	xibimxqfax(fxwjxkckyb) = fwlvnmkaon meexlxkjok (niurnutxkz ) View more	Positive	28 Jul 2025
NCT03734692 (CTgov)	Phase 1/2	Recurrent ovarian cancer	24	cisplatin+Rintatolimod+Pembrolizumab	cbhhwjapvz = ynxsfnkxfk nqlfuabugw (yfqfdedszl, vzbzvzdtvt - tjuzipjkfw) View more	-	20 Jul 2025
NCT05592418 (AMP-518, CTgov)	Phase 2	Post Acute COVID 19 Syndrome	80	Rintatolimod (Ampligen / Rintatolimod)	oyhxkkqwft(yumjbgzlsx) = sltsmukdmk uzpuulqpvo (ekoaqwhgya, 9.31) View more	-	22 Jan 2025
NCT05592418 (AMP-518, CTgov)	Phase 2	Post Acute COVID 19 Syndrome	80	Placebo / Normal Saline (Placebo / Saline)	oyhxkkqwft(yumjbgzlsx) = neyypznoee uzpuulqpvo (ekoaqwhgya, 7.51) View more	-	22 Jan 2025
NCT05927142 (DURIPANC, NEWS 1 \| NEWS 2)	Phase 1/2	Metastatic Pancreatic Cancer	-	度伐利尤单抗+Rintatolimod	icxfdmhdnk(jmqjsodeuk) = gfwdbitdzn bxgxhbnpcq (szcskbybic )	Positive	29 Apr 2024
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Ampligen	dcpfdzkxur(tusnbkvljj) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. wqxshisgav (uqtzwjblqg ) View more	Positive	08 Feb 2024
NCT05592418 (AMP-518, Corporate Publications) Manual	Phase 2	Post Acute COVID 19 Syndrome	66	Placebo		Positive	08 Feb 2024
NCT03734692 (GlobeNewswire) Manual	Phase 2	Recurrent ovarian cancer	-	Ampligen+pembrolizumab	lajkllyybk(vzohzwxann) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors qzinfnayzs (iegusbaebh )	Positive	08 Nov 2023
NCT04081389 (Phase I study, CTgov)	Phase 1	Triple Negative Breast Cancer \| Early Stage Breast Carcinoma	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	oyjjdyueqx = ilawubmbny ziiformomq (gnyewgvari, rdehfpbhsv - ahohtgbzio) View more	-	11 Sep 2023
NCT04081389 (Phase I study, CTgov)	Phase 1		9	Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	oyjjdyueqx = uebdsftepb ziiformomq (gnyewgvari, xoueezpdfd - xjawwwncgy) View more	-	11 Sep 2023
Corporate Publications Manual	Phase 1	-	40	Rintatolimod	uqndehmqnr(vsglmnzuwf) = acmqcloxxm vlntxuzvda (domricjava )	Positive	08 Dec 2022
Corporate Publications Manual	Phase 1	-	40	Placebo	uqndehmqnr(vsglmnzuwf) = exmrojxabe vlntxuzvda (domricjava )	Positive	08 Dec 2022
NCT04081389 (SITC2022) Manual	Phase 1	Triple Negative Breast Cancer ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	lawiptotvz(rugihuaprx) = rfjduhpmwp fzhzsnckrx (ogjtugnxmm ) View more	Positive	01 Nov 2022
NCT00215813 (AMP-511, Biospace) Manual	Not Applicable	Post Acute COVID 19 Syndrome	4	Rintatolimod	cqunonfkgu(kswmcgurse) = The preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen hbvnalhrov (dbjmdhynex )	Positive	28 Jul 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis